Enlivex Therapeutics (NASDAQ:ENLV) and Korro Bio (NASDAQ:KRRO) Head to Head Survey

Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Korro Bio and Enlivex Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
Enlivex Therapeutics	1	1	1	1	2.50

Korro Bio currently has a consensus price target of $16.71, indicating a potential upside of 57.09%. Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 5,792.86%. Given Enlivex Therapeutics’ higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Korro Bio.

Insider & Institutional Ownership

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Korro Bio has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Earnings and Valuation

This table compares Korro Bio and Enlivex Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39 million	24.01	-$117.26 million	($11.67)	-0.91
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.51

Enlivex Therapeutics has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Korro Bio and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Enlivex Therapeutics	N/A	248.08%	206.39%

Summary

Enlivex Therapeutics beats Korro Bio on 8 of the 14 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.